WO1993015234A1 - Facteur xiii active - Google Patents

Facteur xiii active Download PDF

Info

Publication number
WO1993015234A1
WO1993015234A1 PCT/DK1993/000016 DK9300016W WO9315234A1 WO 1993015234 A1 WO1993015234 A1 WO 1993015234A1 DK 9300016 W DK9300016 W DK 9300016W WO 9315234 A1 WO9315234 A1 WO 9315234A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
factor xiii
buffer solution
activated
composition according
Prior art date
Application number
PCT/DK1993/000016
Other languages
English (en)
Inventor
Birger Rostgård JENSEN
Bent Riber Petersen
Ivan Diers
Paul Douglas Bishop
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to AU34490/93A priority Critical patent/AU665805B2/en
Priority to BR9305768A priority patent/BR9305768A/pt
Priority to JP5512862A priority patent/JPH07506001A/ja
Priority to EP93903183A priority patent/EP0726943A1/fr
Publication of WO1993015234A1 publication Critical patent/WO1993015234A1/fr
Priority to FI943458A priority patent/FI943458A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

Definitions

  • the present invention relates to an activated Factor XIII product with improved properties, a composition comprising the 5 activated Factor XIII, and a process for producing activated Factor XIII.
  • Factor XIII also known as plasma transglutaminase is one of the components of the blood coagulation system, and circulates
  • Activated Factor XIII catalyses the crosslinking of fibrin polymers by introducing covalent bonds between non-covalent fibrin polymers. More specifically, activated Factor XIII catalyses the formation of
  • Factor XIII circulates as a tetrameric complex consisting of two a subunits (Mr of about 83 kD) containing the catalytic site of the enzyme and two b subunits (Mr of about 80 kD) (S.I. Chung et al., J. Biol. Chem. 249. 1974, pp. 940-950).
  • the b subunits are cleaved off.
  • a 4 kD fragment is cleaved off the N-terminal end of each of the a subunits (Schwartz et al., J. Biol. Chem. 248. 1973, pp. 1395-1407).
  • the potential catalytic site is located in the a chain with cysteine at the active centre.
  • Factor XIII Due to its function in the coagulation process, Factor XIII has been used for treating patients with postoperative wound healing disorders (Mishima et al., Chirur ⁇ . 55. 1984, pp. 803- 808) and scleroderma (Delbarre et al., Lancet 2., 1981, p.204) . Furthermore, Factor XIII has been used as a component of tissue 10 adhesives (US 4,414,976; US 4,453,939; US 4,377,572; US 4,362,567; US 4,298,598) and has been suggested for use in antifibrinolytic therapy for the prevention of postoperative bleeding and in the treatment of subarachnoid haemorrhage, ulcerative colitis and general wound healing.
  • transglutaminase has been added to minced meat and fish paste (cf. for instance JP 2-255060 to Ajinomoto, JP 2-
  • Transglutaminase has been added to gelatin to make highly polymerised gelatin products (cf. JP 2-86743 to Ajinomoto) .
  • the present invention relates to activated stable Factor XIII.
  • stable refers to the storage stability of the activated Factor XIII and is intended to indicate that the activated Factor XIII preparation retains at least 60% of its initial activity after about 3 months.
  • the present invention relates to a composition
  • a composition comprising activated stable Factor XIII in freeze- dried form or in the form of a frozen liquid concentrate.
  • the invention relates to a method of producing a processed meat product with improved water-binding and consistency properties, the method comprising mixing the composition of the invention with a meat material and incubating the mixture for a period of time sufficient to let the activated Factor XIII react with proteins present in the meat material.
  • this method may be used in the preparation of restructured meat products, e.g. processed ham, containing finely diced meat, or emulsified meat products such as sausages or chopped beef or pork, optionally together with soy protein.
  • the Factor XIII composition may be added to the meat material before, during or after dicing or blending. After incubation, the mixture may be put into appropriate containers such as sausage casings or tins and boiled.
  • the invention also relates to a method of producing a fish paste product with improved consistency properties, the method comprising mixing composition of the invention with a fish meat material and incubating the mixture for a period of time sufficient to let the activated Factor XIII react with proteins present in the fish meat material.
  • the Factor XIII composition of the invention may be used for the production of sausage casings by crosslinking of collagen, for making gelatin gels, in cheese- making for improving the yield of cheese by crosslinking soluble whey proteins, in baking for strengthening gluten, and in the food industry for making edible protein films for wrapping meat or fish products.
  • the Factor XIII composition may be used generally for the crosslinking of proteins, e.g. for immobilisation, precipitation or modification of the properties of a protein (such as changes in pi, hydrophilicity, hydrophobicity, etc.).
  • activated Factor XIII of the invention for medical purposes.
  • medical applications include, but are not limited to postoperative wound healing, inclusion in tissue adhesives, antifibrinolytic therapy, treatment of ulcerative colitis, cf. EP 268 772 and the references cited therein.
  • the present invention relates to a process for producing activated Factor XIII, the process comprising contacting Factor XIII precursor with an immobilised proteolytic enzyme, and collecting the activated Factor XIII in a buffer solution containing one or more stabilisers, or contacting Factor XIII precursor in a buffer solution containing one or more stabilisers with an immobilised proteolytic enzyme.
  • the term "Factor XIII precursor” is intended to indicate the zymogen form of Factor XIII, i.e. the a 2 dimer (2 x 83 kD) , also known as placental Factor XIII, or the a 2 b 2 tetramer, also known as plasma Factor XIII.
  • the invention relates to a process of producing activated Factor XIII, the process comprising contacting Factor XIII precursor with a proteolytic enzyme in a buffer solution containing one or more stabilisers, followed by addition, after a suitable interval, of a protease inhibitor.
  • the Factor XIII product of the invention may conveniently be provided in the form of a Factor XIII a 2 dimer (i.e. placental Factor XIII) .
  • the Factor XIII product may be in the form of an a'a dimer or a'a' dimer.
  • the a'a dimer form is one in which a 4 kD fragment has been cleaved off the N-terminal end of one of the a monomers
  • the a'a' dimer form is one in which a 4 kD fragment has been cleaved off the N-terminal end of both a monomers.
  • the Factor XIII product of the invention is advantageously a recombinant protein since this is a more reliable and economical source of Factor XIII than plasma.
  • the preparation of recombinant Factor XIII in yeast is described in, for instance, EP 268 772 to ZymoGenetics as well as P.D. Bishop et al., Biochemistry 29. 1990, pp. 1861-1869, the contents of which are incorporated herein by reference.
  • Factor XIII precursor as defined above may be activated with an immobilised proteolytic enzyme.
  • suitable enzymes are thrombin, trypsin or a trypsin-like enzyme (e.g. a protease obtainable from a species of Fusarium. cf. WO 89/06270) .
  • the proteolytic enzyme may suitably be immobilised by one of the procedures described in K. Mosbach (ed.), "Immobilized Enzymes” in Methods in Enzymology 44. Academic Press, New York, 1976, including covalent coupling to insoluble organic or inorganic supports, entrapment in gels and adsorption to ion exchange resins or other adsorbent materials.
  • Suitable support materials for the immobilised enzyme are, for instance, plastics (e.g. polypropylene, polystyrene, polyvinylchloride, polyurethane, latex, nylon, teflon, dacron, polyvinylacetate, polyvinylalcohol or any suitable copolymer thereof) , polysaccharides (e.g. agarose or dextran) , ion exchange resins (both cation and anion exchange resins) , silicon polymers (e.g. siloxane) or silicates (e.g. glass) .
  • plastics e.g. polypropylene, polystyrene, polyvinylchloride, polyurethane, latex, nylon, teflon, dacron, polyvinylacetate, polyvinylalcohol or any suitable copolymer thereof
  • polysaccharides e.g. agarose or dextran
  • ion exchange resins both cation and
  • the Factor XIII precursor may be contacted with a proteolytic enzyme after which a protease inhibitor is added.
  • the protease inhibitor may suitably be a trypsin inhibitor such as aprotinin or soybean trypsin inhibitor.
  • the buffer solution into which the activated Factor XIII is collected is preferably a glycine, alanine or borate buffer.
  • the stabiliser or stabilisers present in the buffer solution as well as in the final Factor XIII composition may be a chelating agent, for instance EDTA, EGTA or citrate.
  • EDTA may be present in a concentration of 2-15 mM, preferably 3-12 mM, more preferably- 5-10 mM.
  • Another stabiliser which may be present in the buffer solution and Factor XIII composition is a reducing agent or another substance capable of preventing oxidation of the active -SH at Cys314 of Factor XIII, e.g. a cysteine or sulfite, or an antioxidant such as ascorbic acid or glutathion.
  • a suitable reducing agent is dithiothreitol (DTT) , which may be present in a concentration of 1-10 mM, preferably 2-7 mM, more preferably .2.5-5 mM.
  • DTT dithiothreitol
  • a further stabiliser which may be present in the buffer solution and Factor XIII composition is a sugar.
  • suitable sugars are lactose, glucose, sucrose, maltose or trehalose.
  • the sugar may be present in an amount of 0.5-5%, preferably 1-2%, by weight.
  • a still further stabiliser which may be present in the buffer solution and Factor XIII composition is casein.
  • calcium ions should be present.
  • a currently preferred stabilising solution comprises 2% lactose, 2% casein, 10 mM EDTA, and 5 mM DTT in 10 mM glycine buffer, pH 8.0.
  • the present composition is in freeze-dried form as this generally results in improved stability.
  • rFXIII recombinant Factor XIII
  • the homogenized cells were diluted approximately
  • rFXIII was isolated by crystallization with ll%(w/v) Na-formiate at 25°C in 5 hours. The crystals were 10 harvested by centrifugation (4000 g in 30 minutes) and freezedried. In this way, two preparations of rFXIII were made: M57 with an initial activity of 285 g/kg, and F435 with an initial activity of 580 g/kg.
  • composition of feed Unless otherwise specified, glycine buffer 1510 mM pH 8.0 was used as the solvent. The concentration of rFXIII in the feed was 0.5, 5, 10 and 15 mg/ml. The mixture of glycine buffer and rFXIII was stirred for 1.5 - 2 hours at room temperature to ensure complete dissolution of rFXIII. pH was adjusted several times with NaOH. The solution was clarified by 20 centrifugation (14400 x g for 10 minutes) followed by filtration through a 0.45 ⁇ m membrane filter.
  • the %-yield calculated in the tables shown below is based on the assayed content of the feed (activated with thrombin) .
  • the assay for Factor XIII activity was carried out by a fluorometric activity assay (referred to in P.D. Bishop et al., supra) .
  • the whole content of the vials was dissolved in 100 ml TANEP buffer (0.1 M Tris-acetate, 0.15 M NaCl, 1 mM EDTA, 0.1% PEG 6000) pH 7,5 in order to avoid erroneous results due to inhomogenieties in the freeze-dried preparations. Samples were further diluted in TANEP buffer pH 7,5 prior to being assayed. The results shown are the average of two determinations.
  • Casein is Hammersten casein (Merck Art. 2242) , D-
  • A. Activation Feed composition 4.2 g F435 in 300 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above. 10 mM DTT in TANEP buffer pH 7.5 was added to the effluent. The results of rFXIII activation appear from Table 1 below (cf. Fig. 1) .
  • Feed composition 8,81 g F435 in 300 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above. Trehalose (1%) , EDTA (10 mM) and DTT (10 mM) were added to the effluent. The results are shown in Table 2 below (cf. Fig. 2) . Table 2
  • Feed composition 2,6 g F435 in 200 ml 10 mM glycine buffer were applied on a Sepharose column on which a trypsin-like protease derived from Fusarium (prepared as described in WO 89/06270) had been immobilised by adding 200 mg of the active enzyme mixed with coupling buffer to 4 g of CNBr-activated Sepharose 4B (available from Pharmacia, Sweden) at pH 7.5. An HR5/10 column was packed to a bed height of 43 mm (bed volume 0,84 ml). Trehalose (1%), EDTA (10 mM) and DTT (10 mM) were added to the effluent. The results are shown in Table 3 below (cf. Fig. 3) . 10
  • Feed composition 6.99 g F435 in200 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above. Trehalose (1%) , 10 mM EDTA and 10 mM DTT were added to the effluent. The results are shown in Table 4 below (cf. Fig. 204) .
  • Feed composition 10.04 g M57 in 300 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above.
  • EDTA 10 E5 or 20 mM (E10)
  • lactose 2 LI
  • 4 % L2
  • casein 0 or 2 % Cl
  • the activation yield is 60%, but when casein is added a yield of 75% is obtained.
  • the freeze-dried preparations containing casein have the highest overall yield regardless of the level of lactose and EDTA.
  • Feed composition 10.07 g M57 in 300 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above. Lactose (2%) and EDTA (10 mM) and varying amounts of casein (0, 1, 2 and 4%) were added to the effluent. Samples were assayed immediately, and some of them were frozen or freeze-dried, while others were kept in the refrigerator. The results are shown in Table 6 below.
  • Feed composition 10.76 g M57 in 300 ml 10 mM glycine buffer pH 108.0 was applied on a trypsin-Sepharose column as described above. Casein (Hammarsten) 2% (C) , EDTA 10 mM (E) , DTT 5 mM (D) and 2% lactose (L) or sucrose (S) were added to the effluent as indicated in Table 7 below. Samples were assayed immediately. Some samples were freeze-dried, others were kept in the 15 refrigerator.
  • Casein (Hammarsten) 2% (C) , EDTA 10 mM (E) , DTT 5 mM (D) and 2% lactose (L) or sucrose (S) were added to the effluent as indicated in Table 7 below. Samples were assayed immediately. Some samples were freeze-dried, others were kept in the 15 refrigerator.
  • the activation yield is high, 80 - 90%.
  • the freeze- dried preparations containing casein, EDTA, DTT and lactose/sucrose give a high over-all yield of about 60%. They show no sign of loss of activity over two months. The same composition results in the most stable samples when kept cold.
  • Feed composition 2.51 g F435 in 300 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above. Casein 2% (C) , lactose 2% (L) , EDTA 10 mM (E) and DTT 0 - 20 mM were added to the effluent. Samples were assayed immediately. Some samples were freeze-dried, others were kept in the refrigerator. The results are shown in Table 8 below.
  • Feed composition 4.82 g F435 in 300 ml 10 mM glycine buffer pH 8.0 was applied on a trypsin-Sepharose column as described above. Trehalose (1%), EDTA (10 mM) , DTT (10 mM) and casein (0-2%) were added to the effluent from the column. Samples were assayed immediately. Some samples were frozen and freeze-dried, others were kept in the refrigerator. The results are shown in Table 9 below.
  • Example 3 (used as a control) was prepared, and the two samples were placed in a water bath for 2 hours at 30°C followed by cooling at 5°C for 24 hours. After the sausage skins had been removed, the control sample was still liquid, while the enzymatically treated sample had solidified into a sausage which was stable at room temperature for several days until it was microbially degraded.
  • Example 3
  • the ingredients were mixed and blended.
  • the pH of the resulting mince was 5.51.
  • the pH was adjusted to 7.0 with NaOH.
  • the mince was divided into four portions as follows: 101. Control.
  • the amount of Factor XIII in the mince is calculated from a percentage of protein in beef of 20%.
  • the samples were tinned and heat treated in a water bath at 2530°C for 2.5 hours followed by treatment at 80°C for 1 hour.
  • the tins were cooled in a water bath at about 20"C and subsequently in a refrigerator over night.
  • the gel strength of the boiled mince was measured by means of an Instron dynamometer (available from Instron, FRG) , using the method described by P.-G. Klettner, Fleischwirtsch. 69 (2), 1989, pp. 225-226. The results of these experiments is shown in Figs. 5-7.
  • the ordinate indicates the force required to compress a 22 mm slice of the mince to a thickness of 2 mm.
  • the graph showing the gel strength figures for mince treated with 0.5% activated Factor XIII (Fig. 5) shows a distinct peak indicating breaking of the gel (as it should) .
  • the graph for mince treated with inactive Factor XIII at the same dosage level shows a less distinct peak (Fig. 6) , while the graph for mince treated with 0.05% inactive Factor XIII shows no peak at all (Fig. 7) .
  • the PVC skin was removed, and the gel strength af the sausages was measured on samples cut to a height of 25 mm by means of a Bloom gelometer available from Griffin and George Ltd. , Great Britain.
  • the strength of the samples was 234 g and 142 g, respectively, corresponding to a gel strength improvement in the enzymatically treated gel of 65%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un facteur XIII stable et activé peut être préparé selon un procédé qui consiste à mettre en contact un précurseur de facteur XIII avec une enzyme protéolytique immobilisée et à recueillir le facteur XIII activé dans une solution tampon contenant au moins un stabilisateur ou à mettre en contact un précurseur de facteur XIII, dans une solution tampon contenant au moins un stabilisateur, avec une enzyme protéolytique immobilisée.
PCT/DK1993/000016 1992-01-22 1993-01-20 Facteur xiii active WO1993015234A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU34490/93A AU665805B2 (en) 1992-01-22 1993-01-20 Activated factor XIII
BR9305768A BR9305768A (pt) 1992-01-22 1993-01-20 Fator XIII ativado composiçao e processo para a produçao do fator XIII ativado
JP5512862A JPH07506001A (ja) 1992-01-22 1993-01-20 活性化因子ｘｉｉｉ
EP93903183A EP0726943A1 (fr) 1992-01-22 1993-01-20 Facteur xiii active
FI943458A FI943458A (fi) 1992-01-22 1994-07-21 Aktivoitu tekijä XIII

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9200022 1992-01-22
ATPCT/DK92/00022 1992-01-22

Publications (1)

Publication Number Publication Date
WO1993015234A1 true WO1993015234A1 (fr) 1993-08-05

Family

ID=8153787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1993/000016 WO1993015234A1 (fr) 1992-01-22 1993-01-20 Facteur xiii active

Country Status (8)

Country Link
EP (1) EP0726943A1 (fr)
JP (1) JPH07506001A (fr)
AU (1) AU665805B2 (fr)
BR (1) BR9305768A (fr)
CA (1) CA2128032A1 (fr)
FI (1) FI943458A (fr)
NZ (1) NZ246865A (fr)
WO (1) WO1993015234A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08245418A (ja) * 1995-03-09 1996-09-24 Behringwerke Ag 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
EP0754463A2 (fr) * 1995-06-05 1997-01-22 Hoechst Japan Limited Préparation liquide stabilisée de facteur de coagulation sanguin XIII
WO1998051803A1 (fr) 1997-05-16 1998-11-19 Novo Nordisk Biotech, Inc. Polypeptides a activite de prolyl dipeptidyl aminopeptidase et acides nucleiques codant ces derniers
GB2350046A (en) * 1999-05-20 2000-11-22 British Sugar Plc Edible compositions comprising amorphous trehalose
WO2001082933A2 (fr) * 2000-04-27 2001-11-08 Sunrise Technologies International, Inc. Compositions et procedes de stabilisation de tissu modifie
US6403127B1 (en) 1997-04-11 2002-06-11 Ajinomoto Co., Inc. Method for producing noodles
EP1905443A1 (fr) * 2005-06-08 2008-04-02 Cellex K.K. Liquide destiné à la prévention d adhésion tissulaire et procédé de prévention d adhésion tissulaire
WO2010074338A1 (fr) 2008-12-26 2010-07-01 味の素株式会社 Préparation enzymatique pour produits de viande à un seul ingrédient et procédé de préparation de produits de viande à un seul ingrédient
WO2010074955A1 (fr) 2008-12-16 2010-07-01 Novozymes, Inc. Polypeptides ayant une activité carboxypeptidase et polynucléotides les codant
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
WO2016210395A1 (fr) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases pour hydrolysats de protéines
WO2022192529A1 (fr) * 2021-03-10 2022-09-15 Curie Co. Inc. Activation de zymogènes par des enzymes protéases immobilisées

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539212A4 (fr) * 2002-07-12 2007-05-02 Medarex Inc Procedes et compositions visant a prevenir la degradation oxydative de proteines
JP4524076B2 (ja) * 2003-04-02 2010-08-11 天野エンザイム株式会社 安定化トランスグルタミナーゼ
ATE521700T1 (de) * 2005-12-22 2011-09-15 Zymogenetics Inc Verfahren zur aktivierung von präthrombin-1
JP5166259B2 (ja) * 2006-06-22 2013-03-21 キッコーマン株式会社 ポリアミンオキシダーゼの安定化方法と基質特異性の改良方法
JP5326324B2 (ja) * 2008-04-01 2013-10-30 東洋紡株式会社 チラミンオキシダーゼの安定化方法およびその組成物
JP5919914B2 (ja) * 2012-03-15 2016-05-18 東ソー株式会社 ホモシステイン測定用前処理試薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311950A2 (fr) * 1987-10-15 1989-04-19 Biotest Pharma Gmbh Procédé de préparation d'une solution stérile de protéine de plasma, qui contient du fibrinogène et du facteur de coagulation XIII
US4917904A (en) * 1987-07-02 1990-04-17 Taiyo Fishery Co., Ltd. Process for the production of transglutaminase-containing food having improved texture
WO1991016931A1 (fr) * 1990-05-10 1991-11-14 Zymogenetics, Inc. AGENTS D'IMAGERIE DE CAiLLOTS ET LEUR EMPLOI

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917904A (en) * 1987-07-02 1990-04-17 Taiyo Fishery Co., Ltd. Process for the production of transglutaminase-containing food having improved texture
EP0311950A2 (fr) * 1987-10-15 1989-04-19 Biotest Pharma Gmbh Procédé de préparation d'une solution stérile de protéine de plasma, qui contient du fibrinogène et du facteur de coagulation XIII
WO1991016931A1 (fr) * 1990-05-10 1991-11-14 Zymogenetics, Inc. AGENTS D'IMAGERIE DE CAiLLOTS ET LEUR EMPLOI

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733702A1 (fr) * 1995-03-09 1996-09-25 BEHRINGWERKE Aktiengesellschaft Préparations stables de transglutaminase et procédé de leur préparation
KR100457485B1 (ko) * 1995-03-09 2005-02-02 쳇엘베 베링 게엠베하 안정한 트란스글루타미나제 제형 및 이의 제조 방법
US6204036B1 (en) 1995-03-09 2001-03-20 Aventis Behring Gmbh Stable transglutaminase preparations and processes for their production
JPH08245418A (ja) * 1995-03-09 1996-09-24 Behringwerke Ag 安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
EP0754463A2 (fr) * 1995-06-05 1997-01-22 Hoechst Japan Limited Préparation liquide stabilisée de facteur de coagulation sanguin XIII
EP0754463A3 (fr) * 1995-06-05 1999-02-03 Hoechst Japan Limited Préparation liquide stabilisée de facteur de coagulation sanguin XIII
US6403127B1 (en) 1997-04-11 2002-06-11 Ajinomoto Co., Inc. Method for producing noodles
WO1998051803A1 (fr) 1997-05-16 1998-11-19 Novo Nordisk Biotech, Inc. Polypeptides a activite de prolyl dipeptidyl aminopeptidase et acides nucleiques codant ces derniers
GB2350046B (en) * 1999-05-20 2002-12-18 British Sugar Plc Edible compositions containing trehalose
US6620791B1 (en) 1999-05-20 2003-09-16 British Sugar Plc Edible compositions containing trehalose
GB2350046A (en) * 1999-05-20 2000-11-22 British Sugar Plc Edible compositions comprising amorphous trehalose
WO2001082933A3 (fr) * 2000-04-27 2002-07-18 Sunrise Technologies Internati Compositions et procedes de stabilisation de tissu modifie
WO2001082933A2 (fr) * 2000-04-27 2001-11-08 Sunrise Technologies International, Inc. Compositions et procedes de stabilisation de tissu modifie
EP1905443A1 (fr) * 2005-06-08 2008-04-02 Cellex K.K. Liquide destiné à la prévention d adhésion tissulaire et procédé de prévention d adhésion tissulaire
EP1905443A4 (fr) * 2005-06-08 2009-12-16 Cellex K K Liquide destiné à la prévention d adhésion tissulaire et procédé de prévention d adhésion tissulaire
US9155751B2 (en) 2005-06-08 2015-10-13 The University Of Tokyo Solution for tissue adhesion prevention and method for tissue adhesion prevention
US8461115B2 (en) 2006-03-16 2013-06-11 Stellaris Pharmaceuticals Aps Methods for local treatment with factor VII
WO2010074955A1 (fr) 2008-12-16 2010-07-01 Novozymes, Inc. Polypeptides ayant une activité carboxypeptidase et polynucléotides les codant
WO2010074338A1 (fr) 2008-12-26 2010-07-01 味の素株式会社 Préparation enzymatique pour produits de viande à un seul ingrédient et procédé de préparation de produits de viande à un seul ingrédient
WO2016210395A1 (fr) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases pour hydrolysats de protéines
WO2022192529A1 (fr) * 2021-03-10 2022-09-15 Curie Co. Inc. Activation de zymogènes par des enzymes protéases immobilisées

Also Published As

Publication number Publication date
EP0726943A1 (fr) 1996-08-21
BR9305768A (pt) 1997-01-28
FI943458A0 (fi) 1994-07-21
CA2128032A1 (fr) 1993-08-05
NZ246865A (en) 1996-10-28
FI943458A (fi) 1994-09-21
AU3449093A (en) 1993-09-01
AU665805B2 (en) 1996-01-18
JPH07506001A (ja) 1995-07-06

Similar Documents

Publication Publication Date Title
AU665805B2 (en) Activated factor XIII
US4377572A (en) Tissue adhesive
EP0123304B1 (fr) Méthode pour stabiliser un activateur de plasminogène de tissu et solution aqueuse stable ou poudre le contenant
Ambrus et al. Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme
Dahlqvist et al. Hydrolysis of β‐galactosides using polymer‐entrapped lactase. A study towards producing lactose‐free milk
JPH05186369A (ja) 治療的用途のためのヒトトロンビン濃厚液の製造法
US4968617A (en) Solid hydrochloride salt of t-PA
JPH0665280B2 (ja) タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
JPH07501517A (ja) 局所用フィブリノーゲン複合体
JP2787317B2 (ja) トロンビン凝固性蛋白質の濃縮物、その製造方法及びその治療的用途
JP2690944B2 (ja) 組織プラスミノーゲンアクチベーター活性を有するタンパク質の高濃度溶液
US20110114524A1 (en) Storage-stable, functionally intact fibrinogen
US4082612A (en) Plasminogen activator complex
JP4010573B2 (ja) 低温殺菌中の血漿を安定化するための組成物および治療学的用途のための低温殺菌血漿溶液
US5204447A (en) Purification of factor xiii
EP0837882A1 (fr) Fraction peptidique de collagene et ses utilisations
CA1283047C (fr) Precurseur de l'activateur du plasminogene stabilise et methode de production
Jamlang et al. Effect of p H, Protein Concentration, and Ionic Strength on Heat Inactivation of Staphylococcal Enterotoxin B
Walker et al. A simplified method for preparation of fibrinogen
Cheftel et al. Effects of high pressure on dairy proteins: a review
RU2045902C1 (ru) Состав для стабилизации плазмы крови в ходе пастеризации и способ пастеризации плазмы крови
Mahoney et al. Stabilization of lactase (Escherichia coli) by milk components and related compounds
EP0047879A1 (fr) Procédé pour préparer des compositions protéiniques modifiées
Váradi et al. Purification and properties of human factor IXa
IE902766A1 (en) Pasteurized glue for joining human or animal tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA FI JP NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2128032

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 943458

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1993903183

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 246865

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1993903183

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993903183

Country of ref document: EP